Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gag:267-274 peptide vaccine
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A peptide vaccine containing the amino acids 267 through 274 of the human immunodeficiency virus (HIV) type 1 Gag protein. It is designed to stimulate the immune system to recognize and target specific HIV antigens.
- Other names
- Gag:267-274 Peptide Vaccine
02
Targets
HIV-TCR (HIV-specific T-cell receptor)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on gag:267-274 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gag:267-274 peptide vaccine.